
Since April 2009, when Vancouver’s Cardiome (TSX:COM) signed a deal with US pharmaceutical giant Merck, it’s been all systems go. That was until October 21st, when a patient enrolled in the vernakalant, a drug designed to treat atrial fibrillation, or an abnormal heart rhythm, trial experienced cardiogenic shock and the trial was suspended. Shares of [...]








